Advanced glycosylation end products in patients with diabetic nephropathy. - Wikidata - wikimedia - TriplyDB

Advanced glycosylation end products in patients with diabetic nephropathy.

Advanced glycosylation end products in patients with diabetic nephropathy.

http://www.wikidata.org/entity/Q44031994

about

Molecular characterization of mammalian dicarbonyl/L-xylulose reductase and its localization in kidney Advanced glycation end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis Tobacco smoke is a source of toxic reactive glycation products Does accumulation of advanced glycation end products contribute to the aging phenotype?Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy Assessment of bone turnover and bone quality in type 2 diabetic bone disease: current concepts and future directions MicroRNAs in Diabetic Nephropathy: From Biomarkers to Therapy Immune dysfunction in uremia—an update Diabetic kidney disease; review of the current knowledge Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality Arterial stiffness, vascular calcification and bone metabolism in chronic kidney disease Loss of CD4 T-cell-dependent tolerance to proteins with modified amino acids Simple non-invasive assessment of advanced glycation endproduct accumulation AGEs, autofluorescence and renal function Advanced glycation end products in human optic nerve head Beyond genetic factors in familial amyloidotic polyneuropathy: protein glycation and the loss of fibrinogen's chaperone activity Advanced Glycation Endproducts and Bone Material Properties in Type 1 Diabetic Mice Inhibitory effect of receptor for advanced glycation end products (RAGE) on the TGF-β-induced alveolar epithelial to mesenchymal transition Evolving pandemic diabetic nephropathy Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients.Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway Advanced glycation end products: a highly complex set of biologically relevant compounds detected by mass spectrometry.Microvascular changes in the diabetic foot.Proteomics reveals novel oxidative and glycolytic mechanisms in type 1 diabetic patients' skin which are normalized by kidney-pancreas transplantation.Tissue-advanced glycation end product concentration in dialysis patients.Serum carboxymethyl-lysine, a dominant advanced glycation end product, is associated with chronic kidney disease: the Baltimore longitudinal study of aging.Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling.SOCS3 overexpression inhibits advanced glycation end product-induced EMT in proximal tubule epithelial cells Pyridine nucleotides in glucose metabolism and diabetes: a review.Diet and Diabetic Kidney Disease: Plant Versus Animal Protein.Attenuation of diabetic nephropathy in streptozotocin-induced diabetic rats by Punica granatum Linn. leaves extract Skin fluorescence correlates strongly with coronary artery calcification severity in type 1 diabetes.Peer support for patients with type 2 diabetes in rural communities of China: protocol for a cluster randomized controlled trial.Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy.Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine The AGE-receptor in the pathogenesis of diabetic complications.Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links.

P2860

Q24292412-429D6F99-E917-4AFA-8605-EBC1DF98B4F6 Q24530074-B68EBA8B-EB34-449F-84B1-1C630C9632C8 Q24561776-7F872493-881E-4381-8D03-F466A7EAA462 Q24597379-A75ACB83-2CB9-4175-B771-22EA1DA8F478 Q24623337-E1FBA175-F41D-408F-9F87-73C617AC9409 Q24632710-916D00EA-291B-4CA6-93E5-6EC9BD082B58 Q24682750-9C5D0966-3B8C-4F37-BB90-1AE8636874FC Q26750574-C0487575-6464-4A7F-AE81-756D95540A06 Q26766102-261F5876-3067-41CC-8194-3E1CB83E7198 Q26829076-892F92D5-4781-4523-8871-8001CD756210 Q26830565-F798837C-B4F5-4A5E-929F-8052DAB11BB1 Q26859793-A6DBAE81-9999-4668-B06D-036F6DC2372A Q27024623-33308332-299E-4BB7-8578-A7309820F3A4 Q28243525-5A56728E-8B03-4554-8A0E-9C4DBC706593 Q28271097-934597D6-2CB0-4379-9C25-BA7BDE88AFD8 Q28301793-3F07F2AE-CCCF-4433-909A-C7F1089E09CE Q28345352-D8137DBC-02E1-43C3-808E-591B069777E7 Q28477682-07B8FB25-5E03-4D47-AB97-713AE3601897 Q28551744-D76C260A-6BB6-466C-89EF-0C05676FB6DD Q29346955-C6D4136D-B352-4032-BE5B-A45FEF0424A5 Q30352538-55CB5B36-D7A4-4538-85C4-19827EF01A4B Q30426632-A0F27048-5A21-4739-98E4-95B5697AF016 Q30440532-A61BE1D3-FA1F-4462-BDC6-B4870669BFBA Q30445160-DC6AFC4E-9913-489D-9C2C-C7CA8D45881B Q30665222-4843794F-B95A-410D-852A-7E0006336CBD Q33255016-74B495D9-8FAB-4B9D-8DDF-4E36DD32F42D Q33548694-666BBEFD-289B-4E40-A0A1-95B80912BBFA Q33571288-3580814A-715F-49A1-872B-50787B7EC5BC Q33691339-388EEA81-52F6-46B6-9EF5-244281AE5E65 Q33711306-63509FB8-CDD0-4C39-9102-C7838CBD23BA Q33744838-C654F3A1-81B4-48C1-9353-9E741A897E5C Q33856582-A1848B17-FEC1-4817-9DB7-DEE6535C3D29 Q33889472-8EB219B1-FD57-4B91-8563-1FC490954FEC Q33896502-40BC92F9-2400-43BF-A4C1-53A883958091 Q33905029-434A542D-46DE-437F-84E2-26DE04617412 Q34045318-77BB483E-09CE-4A60-B015-DA6DDF541C36 Q34111608-6E4DEC78-3D70-40F8-B5D1-EB0764692EC6 Q34374197-8DFD2E4E-2BB3-4D2A-8FCD-178F73B9EC6A Q34470639-E1EFEE59-2177-44C3-82B6-EC1D2ABEA660 Q34481838-43DE866B-0CB1-412B-A3B0-336B7D0492CA

P2860

Advanced glycosylation end products in patients with diabetic nephropathy.

http://www.wikidata.org/entity/Q44031994

description

1991 nî lūn-bûn

@nan

1991年の論文

@ja

1991年学术文章

@wuu

1991年学术文章

@zh-cn

1991年学术文章

@zh-hans

1991年学术文章

@zh-my

1991年学术文章

@zh-sg

1991年學術文章

@yue

1991年學術文章

@zh

1991年學術文章

@zh-hant

name

Advanced glycosylation end products in patients with diabetic nephropathy.

@en

Advanced glycosylation end products in patients with diabetic nephropathy.

@nl

type

label

Advanced glycosylation end products in patients with diabetic nephropathy.

@en

Advanced glycosylation end products in patients with diabetic nephropathy.

@nl

prefLabel

Advanced glycosylation end products in patients with diabetic nephropathy.

@en

Advanced glycosylation end products in patients with diabetic nephropathy.

@nl

P1433

Q44031994-62B35B50-C0CB-404B-92E8-E07F60A6C8ED

P1476

Q44031994-21BB0C60-AB2F-471C-9D2D-867325C14F15

P2093

Q44031994-207110F3-F2D9-4E18-A715-01C18AC53248

Q44031994-269B097B-85B4-4D55-B005-97D47D409C8E

Q44031994-2707487B-B404-4896-A025-1906F7792437

Q44031994-446962A7-E7ED-43B7-B458-D2CAEB5C5264

Q44031994-5E725AB4-42F0-47F9-BE46-5B7A3DE6D9B0

Q44031994-71CD27A6-667C-4B30-9296-F95F9CC1BC6C

Q44031994-7F529AAA-BDD5-4D25-B912-AF538B7FD903

Q44031994-E0624806-C4D6-4ED0-868B-B20D08EFB829

Q44031994-E6BC4079-80B9-4298-BDA2-42DAD592AD25

P304

Q44031994-7069FCBB-4EE7-403D-9538-595EC5C28ABF

P31

Q44031994-36AE28D8-4DCD-40ED-9B97-5A4B1A2B8C35

P356

Q44031994-E0F605A1-CB34-474B-803B-2E93BAC8AACC

P407

Q44031994-5365DD80-45FD-45BE-A8EE-A67880FA2B7E

P433

Q44031994-6C7E6F9C-902F-4909-9105-9BD0695925DC

P478

Q44031994-6F968534-FDAB-4316-81C9-44F5AF150762

P577

Q44031994-E528D487-4416-4282-9086-CAF908F2FBCF

P698

Q44031994-92914F58-4F12-42B8-B151-20B74AE12FF9

P921

Q44031994-E846617F-888A-4307-B96E-9D7C6208B287

Q44031994-EC78F4DC-69E9-417A-A478-8A08FE918C67

P356

NEJM199109193251202

P1433

The New England Journal of Medicine

P1476

Advanced glycosylation end products in patients with diabetic nephropathy.

@en

P2093

Cerami A

http://www.w3.org/2001/XMLSchema#string

Delaney V

http://www.w3.org/2001/XMLSchema#string

Friedman EA

http://www.w3.org/2001/XMLSchema#string

Makita Z

http://www.w3.org/2001/XMLSchema#string

Radoff S

http://www.w3.org/2001/XMLSchema#string

Rayfield EJ

http://www.w3.org/2001/XMLSchema#string

Skolnik E

http://www.w3.org/2001/XMLSchema#string

Vlassara H

http://www.w3.org/2001/XMLSchema#string

Yang Z

http://www.w3.org/2001/XMLSchema#string

P304

836-842

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJM199109193251202

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

325

http://www.w3.org/2001/XMLSchema#string

P577

1991-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

1875967

http://www.w3.org/2001/XMLSchema#string

P921